Helius Medical Technologies (DB:26H) - Aandelenkoers, Nieuws & Analyse

26H Overzicht aandelen

A neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma.

Over het bedrijf

26H fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

De winst zal naar verwachting met 69.62% per jaar groeien

De winst is de afgelopen 5 jaar met 10.2% per jaar gegroeid

Risicoanalyse

Heeft geen betekenisvolle marktkapitalisatie ( €4M )

Heeft een omzet van minder dan 1 miljoen USD ( $792K )

Aandelen zijn zeer illiquide

Heeft minder dan 1 jaar cash runway

Helius Medical Technologies, Inc. Concurrenten

MagForce

XTRA:MF6

€3.6m

Audientes

DB:AUG

€6.9m

Geratherm Medical

XTRA:GME

€17.6m

aap Implantate

XTRA:AAQ1

€22.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Helius Medical Technologies
Historische aandelenkoersen
Huidige aandelenkoers	US$5.40
52 Week Hoogtepunt	US$18.50
52 Week Laag	US$5.00
Bèta	1.23
11 maand verandering	0%
3 maanden verandering	-8.47%
1 Jaar Verandering	-55.74%
33 jaar verandering	-99.03%
5 jaar verandering	-99.96%
Verandering sinds IPO	-99.97%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	26H	DE Medical Equipment	DE Markt
7D	0%	4.6%	-1.4%
1Y	-55.7%	0.4%	11.8%

Rendement versus industrie: 26H presteerde slechter dan de German Medical Equipment -sector, die het afgelopen jaar een rendement van 0.4 % opleverde.

Rendement versus markt: 26H presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 11.8 % opleverde.

Prijsvolatiliteit

Is 26H's price volatile compared to industry and market?
26H volatility
26H Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	5.3%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van 26H is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 26H in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2014	26	Dane Andreeff	heliusmedical.com

Helius Medical Technologies, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Helius Medical Technologies zich tot de beurswaarde?
26H fundamentele statistieken
Marktkapitalisatie	€3.44m
Inkomsten(TTM)	-€11.88m
Inkomsten(TTM)	€741.15k

4.6x

P/S-verhouding

-0.3x

Koers/Winstverhouding

Is 26H overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
26H resultatenrekening (TTM)
Inkomsten	US$792.00k
Kosten van inkomsten	US$643.00k
Brutowinst	US$149.00k
Overige uitgaven	US$12.84m
Inkomsten	-US$12.69m

Laatst gerapporteerde inkomsten

Sep 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-22.42
Brutomarge	18.81%
Nettowinstmarge	-1,602.40%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde 26H op de lange termijn?

Bekijk historische prestaties en vergelijking

26H Overzicht aandelen

Beloningen

Risicoanalyse

Helius Medical Technologies, Inc. Concurrenten

XTRA:MF6

€3.6m

DB:AUG

€6.9m

XTRA:GME

€17.6m

XTRA:AAQ1

€22.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Helius Medical Technologies, Inc. Announces Positive Preliminary Results of the PoNSTEP Study

Helius Medical Technologies Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Helius Medical Technologies, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Helius Medical Technologies, Inc. Completes Site Participation Enrollment for Its U.S. Registrational Program in Stroke

Helius Medical Technologies, Inc., Annual General Meeting, Jun 27, 2024

Helius Medical Technologies, Inc. Announces Pons Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts

Recent updates

Helius Medical Technologies, Inc. Announces Positive Preliminary Results of the PoNSTEP Study

Helius Medical Technologies Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Helius Medical Technologies, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Helius Medical Technologies, Inc. Completes Site Participation Enrollment for Its U.S. Registrational Program in Stroke

Helius Medical Technologies, Inc., Annual General Meeting, Jun 27, 2024

Helius Medical Technologies, Inc. Announces Pons Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts

Helius Medical Technologies, Inc. to Report Q1, 2024 Results on May 13, 2024

Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center

Helius Medical Technologies, Inc. has filed a Follow-on Equity Offering.

Helius Medical Technologies Receives Written Notice from the Nasdaq Stock Market

Helius Medical Technologies, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke

Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients

Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital

Helius Medical Technologies, Inc. Announces Impairment Charges for the Three Months Ended September 30 2023

Helius Medical Technologies, Inc. Announces Study Results Demonstrating That PoNS Therapy(TM) Helps Patients with Traumatic Brain Injury Return to Work

Helius Medical Technologies, Inc. Provides Financial Guidance for the Third Quarter of 2023

Helius Medical Technologies, Inc. Provides Financial Guidance for the Third Quarter of 2023

Helius Medical Technologies, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Helius Medical Technologies, Inc. Compliant with All Applicable Nasdaq Listing Criteria

Helius Medical Technologies, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2023

Helius Medical Technologies, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Helius Medical Technologies, Inc. to Report Q1, 2023 Results on May 11, 2023

Helius Medical Technologies to Showcase PoNS Therapy™ at American Physical Therapy Association’s 2023 Combined Sections Meeting

Helius Medical Technologies, Inc. Provides Revenue Guidance for the fourth quarter and Full Year Ended December 31, 2022

Helius Medical Technologies, Inc. Provides Revenue Guidance for the Forth Quarter and Full Year Ended December 31, 2022

Helius Medical Technologies, Inc. Reports Impairment Results for the Quarter Ended September 30, 2022

Helius Medical Technologies, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Helius Medical Technologies Receives Non-Compliance Notice from Nasdaq

Helius Medical Technologies, Inc. Provides Revenue Guidance for the Third Quarter for 2022

Helius Medical Technologies, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Helius Medical Technologies, Inc. Announces Online Training for PoNS Therapy

Helius Medical Technologies, Inc. Announces Launch of Patient Therapy Access Program for PoNS®

Helius Medical Technologies, Inc. Provides Earnings Guidance for the Second Quarter of 2022

Helius Medical Technologies, Inc. to Report Q1, 2022 Results on May 12, 2022

Helius Medical Technologies, Inc. Introduces Device in U.S. to Help Multiple Sclerosis Patients Improve Walking Ability

Helius Medical Technologies, Inc., Annual General Meeting, May 23, 2022

Helius Medical Technologies, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter of 2021

Helius Medical Technologies, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC

Helius Medical Technologies Announces Voluntary De-Listing from Toronto Stock Exchange

Second quarter 2021 earnings released: US$2.58 loss per share (vs US$2.90 loss in 2Q 2020)

Helius Medical Technologies, Inc. Provides Revenue Guidance for the Second Quarter of 2021

Helius Medical Technologies, Inc. Not Providing Earnings Guidance for 2021, Due to COVID-19

Helius Medical Technologies, Inc. Appoints Sherrie Perkins to the Board of Directors

Helius Medical Technologies, Inc. Not to Provide Formal Financial Outlook for the Full Year 2021 At This Time

Helius Medical Technologies, Inc. to Report Q4, 2020 Results on Mar 10, 2021

Helius Medical Technologies, Inc. has completed a Composite Units Offering in the amount of $9.599981 million.

Helius Medical Technologies, Inc. Regains Compliance with Nasdaq Listing Standards

Helius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the Ponstm Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis

New 90-day low: €0.30

Revenue beats expectations

Third quarter 2020 earnings released: US$0.077 loss per share

Helius Medical Technologies, Inc. to Report Q3, 2020 Results on Nov 12, 2020

Helius Medical Technologies, Inc. announced that it has received $3.44419 million in funding from Maple Leaf Investments and other investors

Helius Medical Technologies, Inc. Announces Partnership with Breakthrough Health for Multiple Sclerosis Insights

Helius Medical Technologies, Inc. Announces CEO Changes

Helius Medical Technologies, Inc. Unable to Estimate the Duration and Impact of the COVID-19 Pandemic on its Financial and Operating Results for the Full Year 2020

Earnings released

Helius Medical Technologies, Inc. to Report Q2, 2020 Results on Aug 12, 2020